Managing Tardive Dyskinesia: New Data from Phase 3 Study of Ingrezza
Check out new data from phase 3 study of Ingrezza for the real-world management of tardive dyskinesia.
Source: psychiatrictimes.com
Eiryw Roberts News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Eiryw Roberts. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Eiryw Roberts Today - Breaking & Trending Today
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD...
Source: prnewswire.com
Neurocrine Biosciences Announces Collaboration With Participants of Tardive Dyskinesia Awareness Week
New research on tardive dyskinesia has also been featured at the 2024 APA Annual Meeting.
Source: psychiatrictimes.com
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
CAHtalyst™ Pediatric Study Baseline Characteristics Data Highlight Need for Novel Treatments in Children and Adolescents with Congenital Adrenal Hyperplasia CAHtalog™ Registry Data of...
Source: marketscreener.com
FDA Approves New Ingrezza Formulation for Patients Who Have Difficulty Swallowing
Each Ingrezza Sprinkle capsule contains oral granules consisting of valbenazine, a vesicular monoamine transporter 2 inhibitor.
Source: clinicaladvisor.com